Latest Breaking News On - Innoviva inc - Page 16 : comparemela.com

Results from Pivotal Phase 3 ATTACK Trial of Investigational Sulbactam-Durlobactam for Treatment of Serious Infections Caused by Acinetobacter Published in The Lancet Infectious Diseases

Sulbactam-durlobactam is the first pathogen-targeted therapy under investigation for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia caused by. | May 11, 2023

United statesKeith kayeCenters for diseaseDrug administrationExchange commissionInnoviva incDivision of allergyEntasis therapeutics incSecurities exchangeGlaxo group limitedAntimicrobial drugs advisory committeeJolla pharmaceutical companyWorld health organizationInnoviva specialty therapeuticsLancet infectious diseasesSerious infections

Results from Pivotal Phase 3 ATTACK Trial of Investigational Sulbactam-Durlobactam for Treatment of

Sulbactam-durlobactam is the first pathogen-targeted therapy under investigation for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia caused by susceptible strains of Acinetobacter baumannii-calcoaceticus complex (Acinetobacter).WALTHAM, Mass. (BUSINESS WIRE) Inn.

United statesKeith kayeJolla pharmaceutical companyDrug administrationSecurities exchangeGlaxo group limitedWorld health organizationEntasis therapeutics incExchange commissionCenters for diseaseDivision of allergyInnoviva incAntimicrobial drugs advisory committeeInnoviva specialty therapeuticsLancet infectious diseasesSerious infections

Innoviva (INVA) Announces Publication of Results from Phase 3 ATTACK Trial

Innoviva (INVA) Announces Publication of Results from Phase 3 ATTACK Trial
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Keith kayeInnoviva incEntasis therapeutics incCenters for diseaseWorld health organizationDivision of allergyDrug administrationAntimicrobial drugs advisory committeeSpecialty therapeuticsLancet infectious diseasesSerious infectionsAcinetobacter baumannii calcoaceticus complexInfectious diseasesRutgers robert wood johnson medicalDisease controlNew drug application

Armata Pharmaceuticals Announces First Quarter 2023 Results and Provides Corporate Update

/PRNewswire/ Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechnology company focused on pathogen-specific.

United statesPierre kymeJoyce allaireBrian varnumArmata pharmaceuticals incDefense health agencyInnoviva incTechnology enterprise consortiumPrnewswire armata pharmaceuticals incInnoviva strategic opportunitiesUs department of defenseLifesci advisorsWarfighter medical research programRecent developmentsChief executive officerMedical technology enterprise consortium

Results from Pivotal Phase 3 ATTACK Trial of Investigational Sulbactam-Durlobactam for Treatment of Serious Infections Caused by Acinetobacter Published in The Lancet Infectious Diseases

Results from Pivotal Phase 3 ATTACK Trial of Investigational Sulbactam-Durlobactam for Treatment of Serious Infections Caused by Acinetobacter Published in The Lancet Infectious Diseases
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesKeith kayeEntasis therapeutics incDivision of allergyGreen room communicationsDrug administrationWorld health organizationAntimicrobial drugs advisory committeeInnoviva incCenters for diseaseJolla pharmaceutical companyExchange commissionSecurities exchangeGlaxo group limitedSpecialty therapeuticsLancet infectious diseases